Assignee
NEORX CORP
US158 patents
Top patents by PatentIndex Score
US6663881B2Dec 16, 2003
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP178 citations99
US6569441B2May 27, 2003
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP213 citations99
US6491938B2Dec 10, 2002
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP166 citations99
US6410587B1Jun 25, 2002
Compounds and therapies for the prevention of vascular and non-vascular pathologies
NEORX CORP94 citations99
US6306421B1Oct 23, 2001
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP227 citations99
US6268390B1Jul 31, 2001
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP210 citations99
US6171609B1Jan 9, 2001
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP496 citations99
US6117911ASep 12, 2000
Compounds and therapies for the prevention of vascular and non-vascular pathologies
NEORX CORP219 citations99
US5733925AMar 31, 1998
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP1,012 citations99
US5595722AJan 21, 1997
Method for identifying an agent which increases TGF-beta levels
NEORX CORP182 citations99
US5391723AFeb 21, 1995
Oligonucleotide conjugates
NEORX CORP1,092 citations99
US5112954AMay 12, 1992
Method of enhancing the effect of cytotoxic agents
NEORX CORP147 citations99
US5075099ADec 24, 1991
Metal radionuclide chelating compounds for improved chelation kinetics
NEORX CORP121 citations99
US4897255AJan 30, 1990
Metal radionuclide labeled proteins for diagnosis and therapy
NEORX CORP275 citations99
US6599928B2Jul 29, 2003
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP106 citations98
US6515009B1Feb 4, 2003
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP258 citations98
US6358989B1Mar 19, 2002
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP135 citations98
US5981568ANov 9, 1999
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP682 citations98
US5811447ASep 22, 1998
Therapeutic inhibitor of vascular smooth muscle cells
NEORX CORP402 citations98
US5770609AJun 23, 1998
Prevention and treatment of cardiovascular pathologies
NEORX CORP154 citations98
US5608060AMar 4, 1997
Biotinidase-resistant biotin-DOTA conjugates
NEORX CORP100 citations98
US5599844AFeb 4, 1997
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
NEORX CORP99 citations98
US5169933ADec 8, 1992
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
NEORX CORP409 citations98
US5106951AApr 21, 1992
Antibody conjugates
NEORX CORP133 citations98
US4988496AJan 29, 1991
Metal radionuclide chelating compounds for improved chelation kinetics
NEORX CORP142 citations98
US5563250AOct 8, 1996
Cleavable conjugates for the delivery and release of agents in native form
NEORX CORP146 citations97
US5252713AOct 12, 1993
Polymeric carriers for non-covalent drug conjugation
NEORX CORP121 citations97
US5116944AMay 26, 1992
Conjugates having improved characteristics for in vivo administration
NEORX CORP170 citations97
US7084171B2Aug 1, 2006
Compounds and therapies for the prevention of vascular and non-vascular pathologies
NEORX CORP41 citations96
US6177551B1Jan 23, 2001
Bridged aromatic substituted amine ligands with donor atoms
NEORX CORP32 citations96
US6015897AJan 18, 2000
Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
NEORX CORP69 citations96
US5945456AAug 31, 1999
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
NEORX CORP42 citations96
US5847007ADec 8, 1998
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
NEORX CORP26 citations96
US5773479AJun 30, 1998
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
NEORX CORP48 citations96
US5630996AMay 20, 1997
Two-step pretargeting methods using improved biotin-active agent conjugates
NEORX CORP51 citations96
US5472985ADec 5, 1995
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
NEORX CORP51 citations96
US5322678AJun 21, 1994
Alteration of pharmacokinetics of proteins by charge modification
NEORX CORP120 citations96
US5283342AFeb 1, 1994
Biotinylated small molecules
NEORX CORP61 citations96
US5242679ASep 7, 1993
Metal radionuclide labeled proteins for diagnosis and therapy
NEORX CORP65 citations96
US5175343ADec 29, 1992
Metal radionuclide labeled proteins for diagnosis and therapy
NEORX CORP71 citations96
US5141648AAug 25, 1992
Methods for isolating compounds using cleavable linker bound matrices
NEORX CORP66 citations96
US5021556AJun 4, 1991
Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
NEORX CORP96 citations96
US4986979AJan 22, 1991
Imaging tissue sites of inflammation
NEORX CORP94 citations96
US4965392AOct 23, 1990
Chelating compounds for metal-radionuclide labeled proteins
NEORX CORP123 citations96
US4867962ASep 19, 1989
Functionally specific antibodies
NEORX CORP73 citations96
US6767531B2Jul 27, 2004
High dose radionuclide complexes for bone marrow suppression
NEORX CORP29 citations95
US6262079B1Jul 17, 2001
Prevention and treatment of cardiovascular pathologies
NEORX CORP42 citations95
US6217869B1Apr 17, 2001
Pretargeting methods and compounds
NEORX CORP209 citations95
US6197789B1Mar 6, 2001
Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NEORX CORP53 citations95
US5976535ANov 2, 1999
Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
NEORX CORP76 citations95
Showing the top 50 of 158 patents by PatentIndex Score.